Wednesday, May 9, 2012

Mitsubishi Tanabe Launches pitavastatin in Indonesia

Mitsubishi Tanable announced today that they have launched pitavastatin in Indonesia. Pitavastatin is a novel statin approved for the treatment of dyslipidemia and has some unique benefits when compared to existing ones. Pitavastatin has a high-density lipoprotein (HDL) cholesterol raising effect, may improve insulin resistance, and has little influence on glucose metabolism, which makes it a potential blockbuster especially in the current scenario when statins are being related with increased risk of diabetes. Besides pitavastatin also has minimal drug drug interactions, which makes it ideal for patients with need for multiple drugs (elderly, renal and hepatic dysfunction).

MT has exclusive rights for promoting pitavastatin in Taiwan and Indonesia from Kowa. MT also has a solid operating base in Indonesia with about 140 MR's.

Pitavastatin was first launched in Japan in 2003 and subsequently launched in Korea (2005), Thailand (2008), China (2009), the US (2010) and recently Lebanon (2011).